Methods for treating against viruses
View Patent ↗A combinatorial method for treating against, or at least inhibiting or suppressing, the proliferation of an internal ribosome entry site utilizing virus (IRES-utilizing virus) in a host in need of treatment involves administering the host a compound, a tautomer, or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting replication of the IRES-utilizing virus in cells, wherein the compound is represented by the formula: wherein each R 1 is independent of the other and represents a halogen atom selected from the group consisting of bromo, chloro, fluoro and iodo; and either separately administering another anti-viral drug and/or pro-drug to the anti-viral drug or co-administering the anti-viral drug and/or the pro-drug with the compound, its tautomer, or its pharmaceutically acceptable salt.
1 . A method for inhibiting the replication of a virus that utilizes an internal ribosome entry site in its replication, comprising:
administering a compound, a tautomer, or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting replication of the virus in cells, and
either separately administering another anti-viral drug and/or a pro-drug of the anti-viral drug, or co-administering the anti-viral drug and/or the pro-drug with the compound, its tautomer, or its pharmaceutically acceptable salt,
wherein the compound is represented by the formula:
wherein
n is 2, R1 represents a halogen atom selected from the group consisting of bromo, chloro, fluoro, and iodo, and R1 is substituted at the 2,4 positions and the 3,5 positions of the phenyl moiety, provided that each R1 can be the same or different; and
wherein the anti-viral drug is acyclovir, a pharmaceutically acceptable salt of acyclovir, or a combination thereof, and
the pro-drug is valacyclovir, a pharmaceutically acceptable salt of valacyclovir, or a combination thereof.
2 . The method according to claim 1 , wherein n is 2 and each R1 is the same and represents bromo, chloro or fluoro.
3 . The method according to claim 1 , wherein the virus is from the family Coronaviridae.
4 . The method according to claim 3 , wherein the virus is SARS-CoV-2.
5 . A method for inhibiting the replication of a virus that utilizes an internal ribosome entry site in its replication, comprising:
administering a compound, a tautomer, or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting replication of the virus in cells, and
either separately administering another anti-viral drug and/or a pro-drug of to the anti-viral drug, or co-administering the anti-viral drug and/or the pro-drug with the compound, its tautomer, or its pharmaceutically acceptable salt
wherein the compound is represented by the formula:
wherein n is 2, and both R1 represent chloro,
wherein the anti-viral drug is acyclovir, a pharmaceutically acceptable salt of acyclovir, or a combination thereof, and
the pro-drug is valacyclovir, a pharmaceutically acceptable salt of valacyclovir, or a combination thereof.
6 . The method according to claim 5 , wherein the virus is from the family Coronaviridae.
7 . The method according to claim 6 , wherein the virus is SARS-COV-2.
8 . A method for inhibiting the replication of a virus that utilizes an internal ribosome entry site in its replication, comprising:
administering a compound, a tautomer, or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting replication of the virus in cells, and
either separately administering another anti-viral drug and/or a pro-drug of to the anti-viral drug, or co-administering the anti-viral drug and/or the pro-drug with the compound, its tautomer, or its pharmaceutically acceptable salt,
wherein the compound is one or more selected from the group consisting of:
wherein the anti-viral drug is acyclovir, a pharmaceutically acceptable salt of acyclovir, or a combination thereof, and
the pro-drug is valacyclovir, a pharmaceutically acceptable salt of valacyclovir, or a combination thereof.
9 . The method according to claim 8 , wherein the virus is from the family Coronaviridae.
10 . The method according to claim 9 , wherein the virus is SARS-COV-2.